Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer - Wu, Y-L; Lu, S; Lu, Y (J Thorac Oncol, 2018)